Doctor Evidence to Deploy Its AI-Enabled SaaS DOC Search™ and DOC Analytics™ Platform for COVID-19 to Accelerate Drug Discovery
Summary
SANTA MONICA, Calif.--(BUSINESS WIRE)--Doctor Evidence (“DRE”) has developed new tools for automated network meta-analysis, to now be used in the hunt for the most effective treatments for COVID-19. DRE is using its first-in-industry DOC Analytics™ platform to generate real-time network meta-analysis for researchers to produce quantitative analysis for any therapeutic question in the global landscape. This approach will inform decision makers with regard to real-time updates from clinical trials for quantitative comparison, analysis, and reporting on relevant outcomes. “ We are breaking new ground in AI-assisted technology at a critical time for healthcare,” says Bob Battista, MBA, FRCPH, FRCP Edin., Co-founder and Chief Executive Officer of DRE. DOC Search™ and Analytics™ are being used as a foundational tool by top 10 industry ranked global pharmaceutical/life science companies that are DRE clients.” DRE is a market leading Software-as-a-Service ("SaaS") company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable knowledge.